Mode
Text Size
Log in / Sign up
N/A N=84 Randomized Double-blind Basic Science

Single Session of tACS in a Depressive Episode

Depression · Major Depressive Disorder · Premenstrual Dysphoric Disorder · Depressive Episode

Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcome: Primary: Change in Alpha Frequency Electrical Activity in Left Frontal Cortex From Stimulation — -0.005; 0.008; 0.004; 0.007 microvolts — p=0.0852

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
XCSITE100 Stimulator Sham (Device); XCSITE100 Stimulator tACS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Aug 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Alpha Frequency Electrical Activity in Left Frontal Cortex From Stimulation
-0.005; 0.008; 0.004; 0.007 0.0852

Summary

Purpose: Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders. Participants: 40 males and females, ages 18-65, with depressed mood; 40 healthy males and females, ages 18-65, free of neurological or psychiatric conditions. Procedures: This is a single visit study with two stimulation conditions (tACS and sham tACS). The session will begin with clinical assessments (including confirmation of diagnosis), followed by an interactive EEG task, then a 7 minute resting state EEG (2 minutes eyes closed, 5 minutes eyes open), followed by the stimulation session (40 minutes of tACS or sham tACS), followed by an additional 5 minute resting state EEG. The stimulation will involved 40 minutes of transcranial alternating current stimulation, 2 mA in amplitude and at individualized alpha frequency (determined by the 2 minutes eyes closed EEG recording; between 8 and 12Hz).

Eligibility Criteria

Inclusion Criteria for individuals with depressed mood:

  • Ages 18-65 years
  • Hamilton Depression Rating Scale score >8
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)
  • Low suicide risk which will be determined through the use of both the Structured Clinical Interview for the DSM-5 and by scoring less than 3 (0,1, or 2) in the Hamilton rating depression scale.
  • Negative pregnancy test for female participants

Exclusion Criteria for individuals with depressed mood:

  • DSM-5 diagnosis of alcohol of substance abuse (other than nicotine) within the 12 months
  • DSM-5 diagnosis of alcohol or substance dependence (other than nicotine) within the last 12 months
  • DSM-5 diagnosis of personality disorder
  • Eating disorder (current or within the past 3 months)
  • Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
  • Neurological disorders, including but not limited to history of seizures (except childhood febrile seizures and electro-convulsive therapy (ECT) induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurysm.
  • Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation
  • History of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation or causing cognitive sequelae
  • History of childhood trauma (determined by the Childhood Trauma Questionnaire)
  • Prior brain surgery
  • Any brain devices/implants, including cochlear implants and aneurysm clips
  • Co-morbid neurological condition (i.e. seizure disorder, brain tumor)
  • Use of illicit drugs, confirmed by a drug test
  • Non English speakers
  • Pregnant or nursing females
  • Current use of benzodiazepines or anti-epileptic drugs

Inclusion Criteria for healthy controls:

  • Ages 18-65 years
  • Hamilton Depression Rating Scale score ≤8
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)
  • Negative pregnancy test for female participants

Exclusion Criteria for healthy controls:

  • History of major neurological or psychiatric illness, including epilepsy
  • Medication use associated with neurological or psychiatric illnesses
  • Currently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions
  • DSM-5 diagnosis of personality disorder
  • First degree relative (parent, sibling, child) with major neurological or psychiatric illness
  • Prior brain surgery
  • Major head injury
  • Any brain devices/implants (including cochlear implants and aneurysm clips)
  • History of childhood trauma (determined by the Childhood Trauma Questionnaire)
  • Use of illicit drugs, confirmed by a drug test
  • Braids or other hair styling that prevents direct access to the scalp (if removal not possible)
  • Skin allergies or very sensitive skin
  • Non English speakers
  • Pregnant or nursing females
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03449979). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search